The only exception so far has been the IMpower150 study, which demonstrated a survival benefit for TKI-pretreated patients with ALK/EGFR-positive NSCLC when the PD-L1 inhibitor atezolizumab was combined with both the antiangiogenic agent bevacizumab and chemotherapy [10, 11]. Here, EGFR is linked to non-small cell lung carcinoma.